Postoperative bioactive adrenomedullin is associated with the onset of ARDS and adverse outcomes in patients undergoing open thoracoabdominal aortic surgery.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Adrenomedullin*/blood ; Respiratory Distress Syndrome*/etiology ; Respiratory Distress Syndrome*/blood ; Postoperative Complications*/etiology ; Postoperative Complications*/blood ; Aortic Aneurysm, Thoracic*/surgery ; Aortic Aneurysm, Thoracic*/blood ; Biomarkers*/blood; Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Sepsis/blood ; Sepsis/etiology ; Multiple Organ Failure/etiology ; Multiple Organ Failure/blood ; Multiple Organ Failure/mortality ; Multiple Organ Failure/diagnosis ; Postoperative Period

Cytokine-mediated systemic inflammation after open thoracoabdominal aortic aneurysm (TAAA) repairs plays a pivotal role in disrupting circulatory homeostasis, potentially leading to organ dysfunction. The bioactive form of adrenomedullin (bio-ADM) is a peptide hormone with immunomodulatory and vasomotor effects, making it a potential diagnostic agent in these cases. This retrospective, bicentric study, conducted between January 2019 and December 2022, recruited 36 elective open TAAA repair patients in two German centres. Serum and plasma samples were collected at multiple time points to measure bio-ADM levels. The primary objective was to evaluate the association of bio-ADM levels with the onset of acute respiratory distress syndrome (ARDS), with secondary endpoints focusing on mortality and SIRS-related morbidity. Results showed a significant association between postoperative bio-ADM levels (12-48 h after surgery) and the onset of ARDS (p < .001), prolonged ventilation (p = .015 at 12h after surgery), atrial fibrillation (p < .001), and mortality (p = .05 at 24h). The biomarker was also strongly associated with sepsis (p = .01 at 12 h) and multi-organ dysfunction syndrome (MODS) (p = .02 at 24 h after surgery). The study underscores the potential utility of bio-ADM as a diagnostic tool for identifying patients at risk of postoperative complications following open TAAA repairs.
(© 2024. The Author(s).)

Int J Mol Sci. 2022 Dec 01;23(23):. (PMID: 36499389)
JAMA. 2016 Feb 23;315(8):801-10. (PMID: 26903338)
JAMA. 2016 Feb 23;315(8):788-800. (PMID: 26903337)
N Engl J Med. 2010 Aug 12;363(7):689-91. (PMID: 20818861)
Chest. 2017 Aug;152(2):312-320. (PMID: 28411114)
BMJ Open. 2019 Feb 19;9(2):e024475. (PMID: 30782906)
Pharmacol Rev. 2002 Jun;54(2):233-46. (PMID: 12037140)
Crit Care. 2018 Dec 21;22(1):354. (PMID: 30583748)
J Cardiovasc Surg (Torino). 2007 Feb;48(1):49-58. (PMID: 17308522)
Vasa. 2020 Apr;49(3):187-194. (PMID: 32011218)
Ann Lab Med. 2019 Sep;39(5):454-463. (PMID: 31037864)
Circulation. 2003 Aug 19;108(7):849-56. (PMID: 12900342)
Ann N Y Acad Sci. 2004 Jun;1024:24-53. (PMID: 15265772)
Intensive Care Med Exp. 2023 Mar 3;11(1):10. (PMID: 36864354)
Peptides. 2006 Apr;27(4):661-6. (PMID: 16226342)
Expert Opin Investig Drugs. 2021 Feb;30(2):95-102. (PMID: 33256482)
Crit Care. 2020 Feb 28;24(1):69. (PMID: 32111263)
Eur Respir J. 2007 May;29(5):1033-56. (PMID: 17470624)
Sci Rep. 2021 Sep 23;11(1):18874. (PMID: 34556700)
Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60. (PMID: 8387282)
J Immunol. 2007 Nov 1;179(9):6263-72. (PMID: 17947702)
PLoS One. 2022 Apr 28;17(4):e0267497. (PMID: 35482727)
Cell Physiol Biochem. 2018;46(4):1650-1667. (PMID: 29694958)
Crit Care. 2016 Nov 28;20(1):387. (PMID: 27890016)
J Intern Med. 2021 Jun;289(6):792-806. (PMID: 33381880)
J Clin Med. 2023 Jan 09;12(2):. (PMID: 36675474)
Crit Care. 2020 Feb 4;24(1):36. (PMID: 32019600)
Ann Surg. 2008 Jul;248(1):117-25. (PMID: 18580215)
Best Pract Res Clin Anaesthesiol. 2016 Sep;30(3):257-69. (PMID: 27650338)
Crit Care. 2014 Feb 17;18(1):R34. (PMID: 24533868)
Intensive Care Med. 2021 Nov;47(11):1284-1294. (PMID: 34605947)
Crit Care. 2018 Feb 27;22(1):52. (PMID: 29486781)
Crit Care Med. 2000 Sep;28(9):3191-7. (PMID: 11008981)
Ann Intensive Care. 2017 Dec;7(1):6. (PMID: 28050899)
J Thorac Dis. 2023 Jul 31;15(7):3984-3997. (PMID: 37559662)
Ann Intensive Care. 2014 Feb 18;4(1):4. (PMID: 24533450)
Eur Heart J. 2023 Mar 21;44(12):1020-1039. (PMID: 36721960)
JAMA. 2012 Jun 20;307(23):2526-33. (PMID: 22797452)
Lancet. 2014 Oct 18;384(9952):1455-65. (PMID: 25390327)
J Appl Lab Med. 2017 Sep 1;2(2):222-233. (PMID: 32630976)
J Vasc Surg. 2015 Feb;61(2):497-503. (PMID: 24275079)
Intensive Care Med. 2009 Nov;35(11):1859-67. (PMID: 19662382)
J Thorac Cardiovasc Surg. 2016 May;151(5):1323-37. (PMID: 26898979)
Chest. 2005 Dec;128(6):3937-54. (PMID: 16354866)
Anesth Analg. 2020 Dec;131(6):1693-1707. (PMID: 33186158)
Intensive Care Med Exp. 2013 Dec;1(1):22. (PMID: 26266791)
Front Med (Lausanne). 2021 May 14;8:628302. (PMID: 34055825)
Crit Care. 2017 Feb 20;21(1):34. (PMID: 28219408)
Crit Rev Immunol. 2015;35(4):277-91. (PMID: 26757392)
Front Cardiovasc Med. 2023 Jan 23;9:1017867. (PMID: 36756642)
Crit Care. 2020 Nov 4;24(1):636. (PMID: 33148300)
Front Immunol. 2018 Feb 19;9:292. (PMID: 29520277)
J Pharm Pharmacol. 2014 Dec;66(12):1734-46. (PMID: 25117796)

148498-78-6 (Adrenomedullin)
0 (Biomarkers)

Date Created: 20240604 Date Completed: 20240604 Latest Revision: 20240614

20240614

PMC11150250

10.1038/s41598-024-63412-1

38834580